Press

PSYC’s Spotlight Media Highlights Revenue Growth and Other Operational Achievements Met in Q3

Oct 13 • 5 min read

PSYC Corporation (OTCPink: PSYC), a media leader focused on the emerging psychedelic and cannabis sectors, is pleased to report a 42% increase in revenue from 2022 Q2 to Q3 and other operational highlights through its wholly owned subsidiary Spotlight Media Corp. (“SMC”). The Company contends that the following details can be viewed as operational highlights that were achieved by…

IntelGenx Says Atai Life Sciences Collaboration Leads to Start of First-in-Human Clinical Study of Oral Thin Film Psychedelic Drug Candidate

Oct 13 • 1 min read

IntelGenx Corp. (IGX.TO) on Thursday provided an update on its collaboration with its strategic partner, Atai Life Sciences (atai) for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx’s polymeric film technologies. Under the first of two current feasibility agreements between the companies, IntelGenx conducted pre-development, formulation development work and clinical supply manufacturing…

PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

Oct 13 • 3 min read

PharmAla Biotech (CSE: MDMA) is excited to welcome Dr. Leah Mayo to the company’s Scientific Advisory Board. Dr. Mayo recently took up the role of Parker Chair in Psychedelics Research at the Department of Psychiatry, the Hotchkiss Brain Institute and the Mathison Centre for Mental Health Research and Education at the University Calgary. Prior to her appointment,…

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Oct 13 • 4 min read

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that its RELIANCE III study (REL-1017-303), evaluating REL-1017 in the monotherapy setting for Major Depressive Disorder (MDD), did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo as…

Field Trip Announces Relaunch and Refresh of Its Award-Winning Psychedelic App

Oct 13 • 3 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW), the global leader in the development and delivery of psychedelic therapies, is pleased to announce that a new version of its award-winning app for psychedelic guidance is now available for download on the App Store and Google Play. Formerly known as ‘Trip’ and now known simply as ‘Field Trip’, the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435